CN104812400A - 使用伏拉塞替的组合治疗 - Google Patents

使用伏拉塞替的组合治疗 Download PDF

Info

Publication number
CN104812400A
CN104812400A CN201380062203.7A CN201380062203A CN104812400A CN 104812400 A CN104812400 A CN 104812400A CN 201380062203 A CN201380062203 A CN 201380062203A CN 104812400 A CN104812400 A CN 104812400A
Authority
CN
China
Prior art keywords
days
aml
treatment cycle
surface area
body surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380062203.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·陶布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN104812400A publication Critical patent/CN104812400A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
CN201380062203.7A 2012-11-30 2013-11-27 使用伏拉塞替的组合治疗 Pending CN104812400A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12195162 2012-11-30
EP12195162.8 2012-11-30
PCT/EP2013/074862 WO2014083058A1 (en) 2012-11-30 2013-11-27 Combination therapy with volasertib

Publications (1)

Publication Number Publication Date
CN104812400A true CN104812400A (zh) 2015-07-29

Family

ID=47325907

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380062203.7A Pending CN104812400A (zh) 2012-11-30 2013-11-27 使用伏拉塞替的组合治疗

Country Status (15)

Country Link
US (2) US20140154304A1 (enExample)
EP (1) EP2925343A1 (enExample)
JP (1) JP2016501208A (enExample)
KR (1) KR20150090091A (enExample)
CN (1) CN104812400A (enExample)
AU (1) AU2013351180A1 (enExample)
BR (1) BR112015011748A2 (enExample)
CA (1) CA2889787A1 (enExample)
CL (1) CL2015001258A1 (enExample)
EA (1) EA201500579A1 (enExample)
IL (1) IL238174A0 (enExample)
IN (1) IN2015DN03075A (enExample)
MX (1) MX2015006592A (enExample)
PH (1) PH12015501113A1 (enExample)
WO (1) WO2014083058A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115414376A (zh) * 2015-11-11 2022-12-02 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
CN116785296A (zh) * 2023-06-06 2023-09-22 河北渤腾医药技术有限公司 一种plk1的抑制剂及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104306336B (zh) * 2014-11-18 2016-08-24 河北天成药业股份有限公司 枸橼酸柔红霉素脂质体注射液的制备工艺
US20230201202A1 (en) * 2020-05-27 2023-06-29 Duke University Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012072505A1 (en) * 2010-11-29 2012-06-07 Boehringer Ingelheim International Gmbh Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20050735B1 (hr) 2003-02-26 2013-08-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg Dihidropteridinoni, metoda za njihovu proizvodnju i upotrebu u obliku lijekova
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
RU2474427C2 (ru) * 2006-12-20 2013-02-10 Универзитетсклиникум Хамбург-Эппендорф Применение тризамещенных соединений глицерина для лечения гематологических злокачественных опухолей
US8092828B2 (en) * 2007-02-16 2012-01-10 Celator Pharmaceuticals, Inc. Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012072505A1 (en) * 2010-11-29 2012-06-07 Boehringer Ingelheim International Gmbh Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QUARELLO P ET AL: "FLAG-liposomal doxorubicin (myocet) regimen for refractory or relapsed acute leukemia pediatric patients", 《JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115414376A (zh) * 2015-11-11 2022-12-02 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
CN116785296A (zh) * 2023-06-06 2023-09-22 河北渤腾医药技术有限公司 一种plk1的抑制剂及其应用
CN116785296B (zh) * 2023-06-06 2025-09-05 河北渤腾医药技术有限公司 一种plk1的抑制剂及其应用

Also Published As

Publication number Publication date
CL2015001258A1 (es) 2015-10-02
EA201500579A1 (ru) 2015-12-30
US20140154304A1 (en) 2014-06-05
EP2925343A1 (en) 2015-10-07
WO2014083058A1 (en) 2014-06-05
IL238174A0 (en) 2015-05-31
PH12015501113A1 (en) 2015-08-17
US20170173023A1 (en) 2017-06-22
CA2889787A1 (en) 2014-06-05
BR112015011748A2 (pt) 2017-07-11
KR20150090091A (ko) 2015-08-05
MX2015006592A (es) 2015-08-05
JP2016501208A (ja) 2016-01-18
AU2013351180A1 (en) 2015-04-30
IN2015DN03075A (enExample) 2015-10-02

Similar Documents

Publication Publication Date Title
US9358233B2 (en) Method for treating acute myeloid leukemia
EP1551409B1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of cancer
US20170173023A1 (en) Combination therapy with volasertib
CN112165945A (zh) 治疗淋巴样恶性疾病之方法
JP7783217B2 (ja) アズブジンを含む抗腫瘍医薬組成物
EP1711188B1 (en) Anti-cancer therapies
JP2024125140A (ja) アズブジンと化学療法剤とを含む抗腫瘍医薬組成物
JP2021063014A (ja) 白血病治療薬
CN114159557A (zh) 一种治疗肿瘤疾病的联合用药组合物及应用
US20190240242A1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
EP3200879B1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome iii
EP3024465A1 (en) Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii
CN116726022A (zh) 一种egfr抑制剂在制备治疗癌症药物中的用途
KR20220100006A (ko) 다중 표적 단백질 키나제 억제제의 용도
JP2025541662A (ja) カピバセルチブ及びベネトクラクスの治療用組み合わせ
CN117281902A (zh) 一种药物组合物在制备治疗黑色素瘤产品中的应用
HK1078771B (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150729

WD01 Invention patent application deemed withdrawn after publication